Related by context. All words. (Click for frequent words.) 73 chronic myeloid leukemia CML 73 Ph + ALL 65 leukemia CML 65 chronic myelogenous leukemia CML 63 cytogenetic responses 61 diagnosed Ph + 61 leukemia ALL 60 Ph + 60 lymphoid blast 59 metastatic malignant 59 T#I mutation 59 imatinib resistant 59 myelodysplastic syndromes 59 acute myeloid leukemia AML 58 CML CP 58 Gleevec resistant 58 chronic myeloid 58 relapsed refractory 58 nilotinib 57 acute myeloid 57 leukemia AML 57 dasatinib 57 chronic lymphocytic leukemia CLL 57 MCyR 56 SPRYCEL ® 56 phase Ph + 56 systemic lupus erythematosus 56 cytogenetic response 56 non metastatic osteosarcoma 55 CHOP chemotherapy 55 refractory CML 55 Omacetaxine 55 refractory chronic myeloid 55 CIMZIA TM 55 eosinophilic asthma 55 lymphoid malignancies 55 systemic lupus erythematosus SLE 55 Amrubicin 55 refractory cutaneous T 55 leukemia CLL 55 systemic ALCL 55 decitabine 55 myeloproliferative diseases 55 gastrointestinal stromal tumors 55 KRAS mutations occur 55 Vandetanib 54 idiopathic thrombocytopenic purpura ITP 54 chronic myelogenous leukemia 54 myelodysplastic syndrome MDS 54 relapsed MM 54 immune thrombocytopenic purpura ITP 54 haematologic 54 antibody MAb 54 CCyR 54 CANCIDAS 54 RoACTEMRA 54 autoantibody positive 54 LHON 54 SJIA 54 TORISEL 54 acute leukemias 54 dasatinib Sprycel ® 54 indolent NHL 54 heterozygous FH 53 hematologic 53 glioblastoma multiforme GBM 53 multiple myeloma MM 53 B CLL 53 Chronic Myeloid Leukemia 53 imatinib 53 imatinib Gleevec 53 Dasatinib 53 lupus nephritis 53 docetaxel chemotherapy 53 Dacogen injection 53 gastrointestinal stromal tumors GIST 53 Clofarabine 53 refractory AML 53 SNT MC# 53 refractory chronic lymphocytic 53 canakinumab 53 Vidaza azacitidine 53 systemic anaplastic large 53 Tasimelteon 53 Jevtana 53 sunitinib malate 53 dual endothelin receptor antagonist 53 juvenile idiopathic arthritis JIA 53 Nilotinib 53 relapsed refractory multiple myeloma 53 AA amyloidosis 53 non splenectomized 53 hour bronchodilation 53 OMAPRO 53 Myelodysplastic Syndrome MDS 52 Hodgkin lymphoma HL 52 chronic idiopathic thrombocytopenic purpura 52 Azedra 52 imatinib mesylate Gleevec 52 vandetanib 52 HuMax EGFr 52 CLL SLL 52 refractory indolent non 52 Gleevec imatinib mesylate 52 Marqibo 52 cutaneous T cell 52 heavily pretreated 52 visilizumab 52 chlorambucil 52 Vaprisol 52 YONDELIS 52 adult chronic ITP 52 aHUS 52 dasatinib Sprycel 52 chronic ITP 52 Bezielle 52 chronic myeloid leukemia 52 galiximab 52 follicular lymphoma FL 52 acute GvHD 52 Pemetrexed 52 cutaneous T 52 relapsed AML 52 Noxafil 52 afatinib 52 sJIA 52 Fabry Disease 52 chronic periodontitis 52 oblimersen 52 refractory metastatic colorectal cancer 52 MGd 52 rALLy 52 IL 1ß 52 Myelofibrosis 52 partial remissions 52 Arranon 52 KRAS wild 52 symptomatic BPH 52 refractory gout 52 mCRC patients 52 UPLYSO 52 4mg/kg 52 MabCampath 52 Fludara 52 HER2 positive metastatic breast 52 receptor tyrosine kinase inhibitor 52 cilengitide 52 progressive PsA 52 Rituxan rituximab 52 ACTEMRA TM 52 Acute Myeloid Leukemia AML 52 gastrointestinal stromal tumor GIST 52 Epratuzumab 52 biologic therapy 52 refractory acute myeloid 51 complete cytogenetic 51 acute myelogenous leukemia AML 51 patients evaluable 51 sitaxsentan 51 juvenile idiopathic arthritis 51 HeFH 51 Diffuse Large B 51 bendamustine 51 Cloretazine 51 acute lymphoblastic 51 myelofibrosis 51 bortezomib Velcade 51 romiplostim 51 imatinib Gleevec ® 51 alvespimycin 51 hypophosphatasia 51 metastatic GIST 51 primary hypercholesterolemia 51 pomalidomide 51 Cutaneous T 51 cell lymphoma CTCL 51 atypical hemolytic uremic syndrome 51 de novo kidney transplant 51 phase Ib 51 Chronic lymphocytic leukemia 51 CIMZIA ™ 51 everolimus tablets 51 Toxicities 51 bevacizumab Avastin ® 51 mCRC 51 hyperphenylalaninemia HPA due 51 lumiliximab 51 imatinib therapy 51 invasive candidiasis 51 oral FTY# 51 T1DM 51 idiopathic thrombocytopenic purpura 51 HGS# 51 FOLFOX chemotherapy 51 Traficet EN 51 TEMODAL 51 VAPRISOL 51 T2DM 51 SPRYCEL 51 cetuximab Erbitux ® 51 miglustat 51 TMC# C# 51 ara C 51 Hydroxyurea 51 Fludarabine 51 severe oral mucositis 51 dose escalation phase 51 Imatinib 51 papillary renal cell carcinoma 51 rilonacept 51 Velcade bortezomib 51 refractory Hodgkin lymphoma 51 lenalidomide Revlimid R 51 Rilonacept 51 FluCAM 51 mycophenolate mofetil MMF 51 metastatic CRC 51 pertuzumab 51 chronic granulomatous disease 51 recurrent glioblastoma multiforme 51 motesanib 51 Acute Myeloid Leukaemia AML 51 Severe Primary IGFD 51 eculizumab 51 TTF Therapy 51 angiogenesis inhibitor 51 schizophrenia CIAS 51 Glioblastoma Multiforme 51 azacitidine 51 CYT# potent vascular disrupting 51 phase IIb clinical 51 chronic plaque psoriasis 51 refractory metastatic 51 ACZ# 51 xanthine oxidase inhibitor 50 Allergic Rhinitis 50 Annamycin 50 HGS ETR1 50 metastatic renal cell 50 weekly subcutaneous injections 50 hepatic encephalopathy HE 50 Aplidin 50 active ankylosing spondylitis 50 castrate resistant prostate cancer 50 leukemia APL 50 vWD 50 SCCHN 50 relapsed ovarian cancer 50 cell acute lymphoblastic 50 tocilizumab 50 desvenlafaxine succinate 50 HSCT 50 Chronic Myelogenous Leukemia CML 50 Ilaris 50 interferon beta therapy 50 relapsed leukemia 50 ixabepilone 50 chronic GVHD 50 OHR/AVR# 50 RRMS patients 50 Genz # 50 myeloproliferative disorders 50 complete remissions 50 overt nephropathy 50 FOLFIRI alone 50 inhibitor RG# 50 Bronchiectasis 50 blood phenylalanine Phe 50 hypomethylating agents 50 ofatumumab 50 chloride secretion 50 ZOLINZA 50 CR CRu 50 idarubicin 50 gefitinib Iressa 50 Alemtuzumab 50 ovarian carcinoma 50 myeloproliferative neoplasms 50 pain palliation 50 Irinotecan 50 MELAS 50 Pegasys ® 50 TREANDA 50 blastic phase 50 Idiopathic Pulmonary Fibrosis 50 riociguat 50 Tyrima 50 Tolvaptan 50 evaluable patients 50 alkylating agent 50 Newly Diagnosed Multiple Myeloma 50 thrombocytopenic 50 GW# [003] 50 pegfilgrastim 50 G6PD deficiency 50 Hepatocellular Carcinoma HCC 50 baminercept 50 plasma uric acid 50 follicular lymphoma 50 beclomethasone dipropionate 50 cisplatin chemotherapy 50 Etanercept 50 sorafenib Nexavar ® 50 idiopathic pulmonary fibrosis IPF 50 HuMax CD4 50 Follicular Lymphoma 50 differentiated thyroid 50 uric acid lowering 50 huN# DM1 50 weekly intravenous infusions 50 relapsing remitting multiple sclerosis 50 8mg/kg 50 phase IIb study 50 Folfox 50 SSc 50 acute PAO 50 adjunctive placebo 50 ribavirin RBV 50 hypercalcemia 50 ponatinib 50 ARIKACE 50 Myelodysplastic Syndrome 50 Kepivance 49 platinum refractory 49 diabetic nephropathy 49 Firazyr 49 ZACTIMA 49 oxypurinol 49 VFEND 49 terlipressin 49 thrombocytopenic patients 49 forodesine 49 plus dexamethasone 49 SERCA2a 49 TNF antagonist 49 proliferative diabetic retinopathy 49 CVP chemotherapy 49 Acute Myelogenous Leukemia AML 49 CAELYX 49 taxane chemotherapy 49 NOMID 49 estramustine 49 EGFR TKI 49 Philadelphia Chromosome Positive 49 corticosteroid dexamethasone 49 hepatorenal syndrome 49 relapsed CLL 49 noninfectious uveitis 49 Ceflatonin 49 ulcerative colitis UC 49 relapsed acute myelogenous 49 invasive aspergillosis 49 receptor inhibitor 49 DOXIL ® 49 FOLFOX6 49 RezularTM 49 HQK 49 naïve HCV 49 depsipeptide 49 recurrent glioblastoma 49 refractory CLL 49 hepatitis C genotype 49 pegylated liposomal doxorubicin 49 relapsing remitting MS RRMS 49 enzastaurin 49 docetaxel Taxotere R 49 Ceflatonin ® 49 histone deacetylase HDAC inhibitor 49 PKC# 49 refractory ovarian cancer 49 bronchial hyperresponsiveness 49 alagebrium 49 Xcytrin 49 CRVO 49 refractory NSCLC 49 Xanafide 49 thalidomide Thalomid 49 brentuximab vedotin 49 temozolomide 49 operable breast cancer 49 Ceplene/IL-2 49 Icatibant 49 alkylating agents 49 doripenem 49 secondary hyperparathyroidism 49 recurrent NSCLC 49 IIa trial 49 relapsed acute lymphoblastic 49 achieved ACR# 49 HER2 + 49 rufinamide 49 azacytidine 49 Pixantrone 49 tyrosine kinase inhibitors 49 oral rivaroxaban 49 Denufosol 49 panitumumab Vectibix 49 achieved PASI 49 Flu Cy 49 AGILECT R 49 INCB# [001] 49 IMGN# 49 opioid induced constipation OIC 49 Gemzar ® 49 Pharmacokinetics PK 49 mutated KRAS gene 49 serum urate levels 49 Mylotarg 49 non Hodgkin lymphomas 49 mycosis fungoides 49 alfa 2a 49 teriflunomide 49 CTAP# Capsules 49 achieved sustained virological 49 treatment naive genotype 49 metastatic renal cell carcinoma 49 COU AA 49 cinacalcet 49 dyslipidaemia 49 GvHD 49 Gefitinib 49 cediranib 48 metastatic kidney 48 myelogenous leukemia 48 dirucotide MBP# 48 #mg/m# [001] 48 LHRH antagonists 48 atopic 48 interferon ribavirin 48 resistant ovarian cancer 48 lymphocytic leukemia 48 demonstrated antitumor activity 48 micafungin 48 bipolar mania 48 diabetic neuropathic pain 48 isoproterenol 48 clofarabine 48 bosentan 48 acute lymphoblastic leukemia 48 relapsing multiple sclerosis 48 glufosfamide 48 neurologic progression 48 HoFH 48 acute promyelocytic leukemia APL 48 Dacogen decitabine 48 diabetic retinopathy DR 48 acute mania 48 Phase IIa trial 48 rheumatoid arthritis RA 48 diabetic gastroparesis 48 sunitinib 48 recurrent malignant glioma 48 venlafaxine XR 48 NAGS deficiency 48 HCV SPRINT 48 Fx #A 48 COPAXONE R 48 BRIM3 48 myelodysplastic syndromes MDS 48 PD LID 48 diabetic macular edema 48 OMNARIS HFA 48 follicular Non Hodgkin 48 Phenoptin 48 non metastatic resectable 48 PsA 48 Rituximab 48 follicular NHL 48 lomitapide 48 virological response 48 dosing cohort 48 idursulfase 48 MYLOTARG 48 pancreatic NET 48 erlotinib Tarceva ® 48 ADPKD 48 PRTX 48 refractory acute promyelocytic 48 Relapsed Refractory 48 intravenous belinostat 48 treprostinil 48 zileuton 48 NOXAFIL Oral Suspension 48 BENLYSTA ® 48 proteasome inhibitor 48 stage IIIb 48 elacytarabine 48 diabetes mellitus DM 48 EOquin TM 48 velafermin 48 low dose cytarabine 48 dysglycemia 48 lucinactant 48 hepatocellular carcinoma 48 investigational compound 48 refractory CTCL 48 HBeAg positive patients 48 standard chemotherapy regimens 48 Tamibarotene 48 alemtuzumab treated 48 Zavesca ® 48 gemcitabine Gemzar ® 48 familial hypercholesterolemia 48 dose escalation clinical 48 AML MDS 48 lymphoma CTCL 48 pancreatic adenocarcinoma 48 HBeAg negative 48 delayed onset CINV 48 lanreotide 48 diagnosed chronic myeloid 48 diabetes mellitus T2DM 48 adalimumab 48 superficial bladder cancer 48 Gleevec imatinib 48 febrile neutropenia 48 previously untreated follicular 48 Onrigin 48 irinotecan chemotherapy 48 Hodgkin lymphoma NHL 48 adriamycin 48 Azacitidine 48 cytarabine 48 pediatric malignancies 48 Retreatment 48 basiliximab 48 methylnaltrexone 48 relapsing MS 48 atherothrombotic 48 Refractory Hodgkin Lymphoma 48 pazopanib 48 celgosivir 48 Adalimumab 48 malignant pleural mesothelioma MPM 48 efalizumab 48 mg/m2 dose 48 heavily pretreated patients 48 virological failure 48 biologic DMARD 48 Paxil paroxetine 48 interstitial pneumonia 48 AP# [003] 48 rindopepimut 48 Acute Myeloid Leukemia 48 metastatic colorectal cancer 48 efaproxiral 48 HBeAg negative patients 48 metastatic hormone refractory 48 mRCC 48 brain tumor glioblastoma multiforme 48 VIDAZA 48 anti angiogenic therapy 48 PAOD 48 EGFR mutation positive 48 cysteamine bitartrate 48 axitinib 48 ruboxistaurin 48 sargramostim 48 refractory Hodgkin 48 cetuximab Erbitux R 48 Cushing Syndrome 48 anti leukemic 48 Herceptin trastuzumab 48 diabetic kidney 48 anthracycline therapy 48 Telintra 48 Non Alcoholic Steatohepatitis 48 gefitinib 48 Torisel 48 Phase 2a trial 48 Sprycel dasatinib 48 AA Amyloidosis 48 dexamethasone Decadron 48 nosocomial pneumonia 47 atherothrombotic events 47 cancer mCRC 47 immunomodulatory therapy 47 oral COTI 47 CYT# QbG# 47 alefacept 47 homozygous familial hypercholesterolemia 47 oral methylnaltrexone 47 Zavesca 47 BH4 47 Certolizumab pegol 47 Ranolazine 47 disease modifying antirheumatic 47 decompensated liver disease 47 AGHD 47 DMARD 47 panitumumab 47 recurrent ovarian cancer 47 Phase IIb trials 47 pegylated interferon alpha 47 diagnosed glioblastoma multiforme 47 potentially hepatotoxic 47 chronic HBV infection 47 Abrupt discontinuation 47 PRT# 47 standard chemotherapy regimen 47 amrubicin 47 recurrent genital herpes 47 gemcitabine carboplatin 47 Aviptadil 47 iniparib 47 diarrhea predominant irritable 47 Inhaled nitric oxide 47 adverse cytogenetics 47 Symadex 47 trastuzumab Herceptin R 47 ciclesonide 47 Solid Tumors criteria 47 imatinib mesylate 47 receiving highly emetogenic 47 prucalopride 47 ziconotide 47 malignant pleural mesothelioma 47 renal toxicity 47 bexarotene 47 relapsing remitting 47 DMARD therapy 47 FOLFOX 47 FOLFOX4 47 grade cervical intraepithelial 47 cetuximab 47 Telcyta 47 mg kg dose 47 hypercholesterolaemia 47 dyslipidemia 47 Bronchitol 47 plasminogen activators 47 velaglucerase alfa 47 FOLFIRI 47 BARACLUDE ® 47 bortezomib refractory 47 evaluating Xcytrin 47 topotecan 47 abiraterone acetate 47 carcinoma mCRC 47 relapsed GBM 47 achieved sustained virologic 47 relapsed multiple myeloma 47 indolent follicular non 47 glioblastoma 47 remission induction 47 castration resistant prostate cancer 47 HIV HCV coinfected 47 paricalcitol 47 PegIntron 47 eltrombopag 47 Plicera 47 C1 INH 47 ceftazidime 47 cardiac repolarization 47 VELCADE 47 cyclophosphamide methotrexate 47 Lenocta 47 hormone angiotensin II 47 pancreatic neuroendocrine tumors 47 inhaled liposomal ciprofloxacin 47 hematologic disorders 47 tolvaptan 47 pegylated interferon alfa 2a 47 dacarbazine 47 cystinosis patients 47 glatiramer acetate 47 paclitaxel poliglumex 47 trabectedin 47 airway hyperresponsiveness 47 carcinoid tumors 47 QD dosing 47 Vectibix 47 amphotericin B 47 peritumoral brain edema 47 IFN beta 47 relapsed Acute Myeloid 47 IV melanoma 47 TMC# [001] 47 Vernakalant 47 PNP inhibitor 47 Teriflunomide 47 non Hodgkin Lymphoma 47 null responder HCV 47 antiretroviral naive 47 immune thrombocytopenic purpura 47 adalimumab Humira 47 Revlimid lenalidomide 47 relapsing remitting MS 47 Ph + CP 47 cyclophosphamide doxorubicin vincristine 47 Arzerra ofatumumab 47 biliary tract cancer 47 Vorinostat 47 HCV RESPOND 2 47 Acute Myelogenous Leukemia 47 ganciclovir 47 thromboembolic events 47 Tanespimycin 47 sorafenib Nexavar 47 nab paclitaxel 47 Fibrillex TM 47 Tracleer R 47 cell lymphoma ALCL 47 RECIST criteria 47 steroid refractory ulcerative 47 macroalbuminuria 47 relapsed myeloma 47 Cinryze ™ 47 metastatic malignant melanoma 47 organophosphate exposure 47 Bosentan 47 prostate carcinoma 47 evaluable 47 MPS VI 47 ARIKACE ™ 47 colorectal adenoma 47 neovascular 47 hyperammonemia 47 SCIg 47 raltegravir 47 deferiprone 47 hormone refractory prostate cancer 47 Bortezomib 47 nilotinib Tasigna ® 47 HCV infected 47 mapatumumab 47 pulmonary arterial hypertension PAH 47 active comparator 46 lapatinib Tykerb 46 astrocytoma 46 Clolar 46 JAK inhibitors 46 pirfenidone 46 Taxotere ® 46 Waldenstrom macroglobulinemia 46 Squalamine 46 rituximab refractory 46 Ambrisentan 46 inhaled iloprost 46 dosing cohorts 46 natalizumab 46 HBeAg positive 46 Natalizumab 46 hepatic fibrosis 46 Moli# 46 Primary IGFD 46 prior chemotherapy regimens 46 nonalcoholic steatohepatitis NASH 46 cabazitaxel 46 Phase 2a clinical 46 PAH 46 rituximab refractory follicular 46 ATACAND 46 etanercept 46 gemcitabine chemotherapy 46 olmesartan 46 anemia hemoglobin 46 polymerase inhibitor 46 nucleoside naive 46 Everolimus 46 placebo controlled clinical trials 46 methotrexate MTX 46 RG# [001] 46 tipifarnib 46 Bcr Abl T#I mutation 46 panobinostat 46 FOLOTYN 46 metastatic gastric 46 masitinib 46 registrational 46 IV NSCLC 46 regorafenib 46 pulmonary hypertension PH 46 dacarbazine DTIC 46 hormone refractory metastatic prostate 46 antiangiogenic therapy 46 basal cell nevus syndrome 46 ISTODAX 46 interferon IFN 46 tacrolimus ointment 46 CR nPR 46 virologic failure 46 goserelin 46 anagrelide 46 Tarceva erlotinib 46 Candida infections 46 favorable pharmacokinetic profile 46 IIa clinical trial 46 DLBCL 46 splenectomized patients 46 vidofludimus 46 HER2 positive breast cancer 46 Letairis ambrisentan 46 Tumor Necrosis Factor 46 refractory myeloma 46 Virulizin ® 46 tumor xenograft models 46 MabThera Rituxan 46 unipolar depression 46 Mimpara 46 lupus renal disease 46 epirubicin 46 Doxil ® 46 tumors GIST 46 metastatic HRPC 46 nitazoxanide 46 Silodosin 46 Pulmonary Arterial Hypertension 46 Miraxion 46 candidemia 46 follicular non 46 macrolide antibiotic 46 salmeterol HFA MDI 46 anthracycline containing 46 unresectable recurrent 46 Privigen 46 mycophenolate mofetil 46 Eltrombopag 46 calcineurin inhibitors 46 Promacta 46 ascending doses 46 dexpramipexole 46 DPP4 inhibitor 46 KRN# 46 MAGE A3 ASCI 46 antibiotic amikacin 46 interferon beta 1b 46 CTEPH 46 von Willebrand disease 46 ritonavir boosted 46 hyperuricemia 46 chronic thromboembolic pulmonary 46 chemoradiation therapy 46 PEGINTRON TM 46 cardiac toxicity 46 palifosfamide 46 remission CR 46 Prolastin C 46 AZILECT ® 46 CRp 46 virologic response 46 HCV infection 46 erlotinib Tarceva 46 vinorelbine 46 rFIXFc 46 cell chronic lymphocytic 46 COPAXONE ® 46 allergic asthma 46 mepolizumab 46 6R BH4 46 Cloretazine ® 46 pegylated interferon alfa 46 Femara letrozole 46 endothelin receptor antagonists 46 partial onset seizures 46 pegaptanib 46 vorinostat 46 prospectively defined 46 Idiopathic Pulmonary Fibrosis IPF 46 mixed hyperlipidemia 46 dose escalation trial 46 uveitis 46 virus HCV protease inhibitor 46 LQTS 46 primary biliary cirrhosis 46 microalbuminuria 46 mg/m2/day 46 cystic fibrosis CF 46 protease inhibitor PI 46 plasma pharmacokinetics 46 acute manic 46 taxane therapy 46 Gamunex C 45 oral Hycamtin 45 risperidone Risperdal 45 Chronic Prostatitis 45 Nocturia 45 FVIIa 45 stage IIIB 45 ULORIC 45 Navelbine ® 45 interferon alfa 45 telaprevir dosed 45 juvenile myelomonocytic leukemia 45 underwent liver transplantation 45 grade glioma 45 unique alkylating agent 45 fluvastatin 45 peginterferon alfa 45 carboplatin 45 octreotide 45 CYP #A# 45 antithyroid 45 C1 INH concentrate 45 beta2 agonist 45 QAB# 45 infliximab therapy 45 beta 1a 45 serum phosphate 45 fibrotic disease 45 Chronic Fatigue Syndrome CFS 45 chronic HCV 45 TACE 45 carboplatin paclitaxel 45 arbaclofen 45 relapsed refractory aggressive 45 refractory SCLC 45 unresectable stage 45 cytotoxic chemotherapy 45 ACV1 45 colorectal liver metastases 45 denileukin diftitox 45 severe gastroparesis 45 severe sepsis 45 refractory indolent NHL 45 clodronate 45 PEGINTRON 45 vinca alkaloid 45 neoadjuvant 45 bronchopulmonary dysplasia 45 acromegalic patients 45 histologically confirmed 45 severe Primary IGFD 45 blinatumomab 45 ISIS # 45 Omnitarg 45 Zerenex 45 PREZISTA r 45 opioid induced constipation 45 tigecycline 45 bevacizumab Avastin 45 overactive bladder OAB 45 zoledronic acid 45 elevated triglyceride levels 45 doublet chemotherapy 45 HRPC 45 Aliskiren 45 anthracyclines taxanes 45 erythropoietic 45 abatacept 45 liposomal doxorubicin 45 LEXIVA r 45 intracranial hemorrhage ICH 45 peginterferon 45 β blockers 45 SHPT 45 primary aldosteronism 45 Acute Lymphocytic Leukemia 45 BMPR2 45 fallopian tube cancers 45 refractory 45 AAT deficiency 45 progressive psoriatic arthritis 45 cerebral vasospasm 45 idebenone 45 myotonic dystrophy 45 arachidonic acid AA 45 interferon alfa 2b 45 myelofibrosis MF 45 reperfusion injury 45 subcutaneous methylnaltrexone 45 relapsed 45 plasma kallikrein 45 dihydrochloride 45 Kuvan 45 atopic dermatitis 45 temsirolimus 45 ER CHOP 45 pegylated interferons 45 Erlotinib 45 atopic disease 45 mineralocorticoid receptor 45 eculizumab therapy 45 APTIVUS r 45 radiotherapeutic 45 pleural mesothelioma 45 lactic acidosis 45 chemo radiotherapy 45 LHRH analogues 45 pulmonary arterial hypertension 45 nicardipine 45 interferon therapy 45 chronic HBV 45 mitoxantrone plus 45 chronic HCV genotype 45 advanced carcinoid 45 sustained virologic response 45 eribulin 45 mildly symptomatic 45 multiple myeloma 45 uricase 45 docetaxel Taxotere 45 fallopian tube carcinoma 45 pancreatic insufficiency 45 coagulation abnormalities 45 vismodegib 45 QVA# 45 Aurora kinase 45 pharmacodynamic PD